MA29626B1 - Formes cristallines de 4-methyl-n-[3-(4-methyl -imidazol-1-yl)-5-trifluromethyl-phenyl]-3-(4- pyridin-3-yl-pyrimidin-2-ylamino)-benzamide - Google Patents

Formes cristallines de 4-methyl-n-[3-(4-methyl -imidazol-1-yl)-5-trifluromethyl-phenyl]-3-(4- pyridin-3-yl-pyrimidin-2-ylamino)-benzamide

Info

Publication number
MA29626B1
MA29626B1 MA30566A MA30566A MA29626B1 MA 29626 B1 MA29626 B1 MA 29626B1 MA 30566 A MA30566 A MA 30566A MA 30566 A MA30566 A MA 30566A MA 29626 B1 MA29626 B1 MA 29626B1
Authority
MA
Morocco
Prior art keywords
methyl
ylamino
benzamide
imidazol
pyrimidin
Prior art date
Application number
MA30566A
Other languages
English (en)
Inventor
Paul W Manley
Wen-Chung Shieh
Paul Allen Sutton
Piotr H Karpinski
Raeann Wu
Stephanie Monnier
Joerg Brozio
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37451227&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA29626(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA29626B1 publication Critical patent/MA29626B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Les formes cristallines de la base libre 4-méthyl-N-[3-(4-méthyl-imidazol-1-yl)-5-trifluorométhyl-phényl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide et de ses sels sont préparées à l'aide de différents procédés.
MA30566A 2005-07-20 2008-01-09 Formes cristallines de 4-methyl-n-[3-(4-methyl -imidazol-1-yl)-5-trifluromethyl-phenyl]-3-(4- pyridin-3-yl-pyrimidin-2-ylamino)-benzamide MA29626B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70140505P 2005-07-20 2005-07-20
US71621405P 2005-09-12 2005-09-12

Publications (1)

Publication Number Publication Date
MA29626B1 true MA29626B1 (fr) 2008-07-01

Family

ID=37451227

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30566A MA29626B1 (fr) 2005-07-20 2008-01-09 Formes cristallines de 4-methyl-n-[3-(4-methyl -imidazol-1-yl)-5-trifluromethyl-phenyl]-3-(4- pyridin-3-yl-pyrimidin-2-ylamino)-benzamide

Country Status (43)

Country Link
US (4) US8343984B2 (fr)
EP (5) EP2284168A3 (fr)
JP (3) JP5289948B2 (fr)
KR (3) KR20130077915A (fr)
CN (2) CN103804356A (fr)
AR (1) AR054846A1 (fr)
AU (2) AU2006276204A1 (fr)
BR (1) BRPI0613615B1 (fr)
CA (1) CA2614334C (fr)
CR (1) CR9657A (fr)
CU (1) CU23916B1 (fr)
CY (2) CY1113076T1 (fr)
DK (2) DK2284167T4 (fr)
EA (2) EA013464B1 (fr)
EC (1) ECSP088119A (fr)
ES (3) ES2623608T5 (fr)
GE (1) GEP20115302B (fr)
GT (1) GT200600315A (fr)
HK (1) HK1116783A1 (fr)
HN (1) HN2008000311A (fr)
HR (2) HRP20120573T1 (fr)
HU (1) HUE031791T2 (fr)
IL (2) IL188189A0 (fr)
JO (1) JO3308B1 (fr)
LT (1) LT2284167T (fr)
MA (1) MA29626B1 (fr)
MX (1) MX2008000899A (fr)
MY (1) MY148554A (fr)
NI (1) NI200800017A (fr)
NO (1) NO341930B1 (fr)
NZ (1) NZ564409A (fr)
PE (1) PE20070214A1 (fr)
PH (1) PH12013501590A1 (fr)
PL (2) PL1912973T3 (fr)
PT (2) PT2284167T (fr)
RS (1) RS55929B2 (fr)
SG (1) SG163620A1 (fr)
SI (2) SI2284167T2 (fr)
SM (1) SMAP200800011A (fr)
TN (1) TNSN08029A1 (fr)
TW (1) TWI406661B (fr)
UA (1) UA94234C2 (fr)
WO (1) WO2007015870A2 (fr)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200600316A (es) * 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
GT200600315A (es) 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
EP2010182A2 (fr) * 2006-04-07 2009-01-07 Novartis AG Utilisation d'inhibiteurs de c-src en combinaison avec un composé pyrimidylaminobenzamide pour traiter la leucémie
EP1923053A1 (fr) 2006-09-27 2008-05-21 Novartis AG Composition pharmaceutique comprenant de la nilotinib ou son sel
ES2459877T3 (es) * 2007-12-21 2014-05-12 Novartis Ag Combinación de nilotinib y clorambucil para el tratamiento de leucemia linfocítica crónica
US20100016590A1 (en) * 2008-07-17 2010-01-21 Teva Pharmaceutical Industries Ltd. Nilotinib intermediates and preparation thereof
PL2262793T3 (pl) * 2008-11-05 2013-01-31 Teva Pharma Formy krystaliczne nilotynibu HCL
EP2186514B1 (fr) 2008-11-14 2016-06-29 Kinki University Traitement de tumeurs malignes de la gaine des nerfs périphériques
RU2011140404A (ru) 2009-03-06 2013-04-20 Новартис Аг Применение производных пиримидиламинобензамида для лечения нарушений, опосредованных киназой, содержащей мотив лейциновой "молнии" и стерильный альфа мотив (zak)
TW201102068A (en) 2009-06-02 2011-01-16 Novartis Ag Treatment of ophthalmologic disorders mediated by alpha-carbonic anhydrase isoforms
JP5948246B2 (ja) 2009-10-23 2016-07-06 ノバルティス アーゲー Ｂｃｒ−ａｂｌ、ｃ−ｋｉｔ、ｄｄｒ１、ｄｄｒ２またはｐｄｇｆ−ｒのキナーゼ活性によって仲介される増殖性障害およびその他の病態の治療方法
JO3634B1 (ar) 2009-11-17 2020-08-27 Novartis Ag طريقة لعلاج اضطرابات تكاثرية وحالات مرضية أخرى متوسطة بنشاط كيناز bcr-abl، c-kit، ddr1، ddr2، أو pdgf-r
IN2010KO00035A (fr) * 2010-01-15 2016-09-02
EP2558098A2 (fr) 2010-04-16 2013-02-20 Novartis AG Traitement d'un cancer du sein résistant à l'endocrine
EP2382976A1 (fr) 2010-04-30 2011-11-02 Hiroshima University Utilisation d'inhibiteurs pdgf-r pour le traitement de métastases dans les ganglions lymphatiques du cancer gastrique
US8937082B2 (en) 2010-06-21 2015-01-20 Teva Pharmaceutical Industries Ltd. Nilotinib salts and crystalline forms thereof
CN102453024B (zh) * 2010-10-27 2014-09-03 浙江九洲药业股份有限公司 一种尼罗替尼盐酸盐晶型及其制备方法
WO2012070062A2 (fr) * 2010-11-26 2012-05-31 Hetero Research Foundation Nouveau polymorphe de chlorhydrate de nilotinib
AR086913A1 (es) * 2011-06-14 2014-01-29 Novartis Ag 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas
CA2853095A1 (fr) 2011-10-28 2013-05-02 Novartis Ag Procede de traitement de tumeurs stromales gastro-intestinales
WO2013063003A1 (fr) 2011-10-28 2013-05-02 Novartis Ag Méthode de traitement des tumeurs stromales gastro-intestinales
CA2855503A1 (fr) 2011-11-14 2013-05-23 Novartis Ag Formulation a liberation immediate de 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-methyl- 1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide
EP2626355B1 (fr) * 2012-02-09 2016-02-03 Natco Pharma Limited Procédé de préparation d'hydrochlorure de nilotinib
WO2013120852A1 (fr) 2012-02-13 2013-08-22 Grindeks, A Joint Stock Company Intermédiaires pour un nouveau procédé de préparation d'imatinib et d'inhibiteurs de tyrosine kinase associés
US9061028B2 (en) 2012-02-15 2015-06-23 Natco Pharma Limited Process for the preparation of Nilotinib
BR112015000349A2 (pt) 2012-07-11 2017-06-27 Novartis Ag método de tratamento de tumores estromais gastrointestinais
WO2014059518A1 (fr) * 2012-10-15 2014-04-24 Apotex Technologies Inc. Formes solides du chlorhydrate de nilotinib
EP2909191B1 (fr) * 2012-10-19 2019-03-20 Basf Se Système cristallin multicomposant comprenant du nilotinib et des formateurs de co-cristal sélectionnés
PT2958916T (pt) * 2013-02-21 2018-11-21 Pfizer Formas sólidas de um inibidor de cdk4/6 seletivo
EP2792360A1 (fr) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide pour utilisation dans le traitement de HCV
AU2014259029B2 (en) 2013-04-24 2018-08-16 Dr. Reddys Laboratories Limited Polymorphic forms of nilotinib hydrochloride
RU2551359C9 (ru) * 2013-11-28 2021-08-20 Общество с ограниченной ответственностью "Мамонт Фарм" Наноразмерная слабо закристаллизованная модификация 4-метил-N-[3-(4-метилимидазол-1-ил)-5-(трифторметил)фенил]-3-[(4-пиридин-3-илпиримидин-2-ил)амино]бензамида гидрохлорида моногидрата, способ ее получения и фармацевтическая композиция на ее основе
WO2015092624A1 (fr) 2013-12-16 2015-06-25 Ranbaxy Laboratories Limited Mono-oxalate de nilotinib et sa forme cristalline
WO2016020891A1 (fr) 2014-08-08 2016-02-11 Dr. Reddy’S Laboratories Limited Procédé de préparation de formes polymorphes du nilotinib
MX2017004770A (es) * 2014-10-16 2017-07-26 Apotex Inc Formas solidas del clorhidrato de nilotinib.
SI3408264T1 (sl) 2016-01-26 2020-07-31 Farma Grs, D.O.O. Nilotinibijev dinitrat (V) in njegove kristalne oblike
WO2017149550A1 (fr) * 2016-03-02 2017-09-08 Msn Laboratories Private Limited Forme amorphe du 4-méthyl-n-[3-(4-méthyl-1h-imidazol-1-yl)-5-(trifluorométhyl)phényl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-benzamide
ES2814499T3 (es) 2016-03-14 2021-03-29 Pliva Hrvatska D O O Formas en estado sólido de sales de Nilotinib
CN106496193A (zh) * 2016-09-13 2017-03-15 福格森（武汉）生物科技股份有限公司 一种高纯度尼罗替尼的制备方法
EP3404025B1 (fr) * 2017-05-16 2019-12-04 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Procede de preparation de nilotinib pur et de son sel
CZ2017821A3 (cs) 2017-12-20 2019-07-03 Zentiva, K.S. Léková forma obsahující krystalický nilotinib
CN115569137A (zh) 2018-06-15 2023-01-06 汉达癌症医药责任有限公司 激酶抑制剂的盐类及其组合物
JP2020007240A (ja) * 2018-07-04 2020-01-16 住友化学株式会社 ベンズアミド化合物の製造方法
EP3877379A4 (fr) * 2018-11-05 2022-08-31 Laurus Labs Limited Forme cristalline de chlorhydrate de nilotinib, son procédé de préparation et composition pharmaceutique le contenant
WO2021155254A1 (fr) 2020-01-31 2021-08-05 Nanocopoeia, Llc Microparticules de nilotinib amorphe et leurs utilisations
IL297776A (en) 2020-04-30 2022-12-01 Nanocopoeia Llc Orally disintegrating tablets containing an amorphous solid dispersion of nalotinib
CN114133378B (zh) * 2020-09-04 2023-08-15 成都苑东生物制药股份有限公司 一种盐酸尼洛替尼共晶及其制备方法
AU2022292092A1 (en) 2021-06-19 2024-02-01 Helm Ag Granulate composition comprising nilotinib
EP4122452A1 (fr) 2021-07-23 2023-01-25 KRKA, d.d., Novo mesto Composition pharmaceutique comprenant du nilotinib et son procédé de fabrication
EP4260848A1 (fr) 2022-04-11 2023-10-18 Lotus Pharmaceutical Co., Ltd. Composition pharmaceutique pour forme posologique solide contenant du nilotinib et son procédé de préparation
CN116102540A (zh) * 2023-01-05 2023-05-12 浙江工业大学 两种尼洛替尼游离碱新晶型及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US701406A (en) 1901-07-16 1902-06-03 Thomas K Jones Cut-off-valve mechanism.
US701405A (en) 1902-02-17 1902-06-03 Archibald White Maconochie Ejecting device for stamping-machines.
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
GB0325031D0 (en) * 2003-10-27 2003-12-03 Novartis Ag Organic compounds
CN101693031A (zh) * 2003-11-18 2010-04-14 诺瓦提斯公司 Kit突变形式的抑制剂
GT200600316A (es) 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
GT200600315A (es) 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida

Also Published As

Publication number Publication date
NI200800017A (es) 2009-03-03
CY1113076T1 (el) 2016-04-13
PT1912973E (pt) 2012-09-03
CN103804356A (zh) 2014-05-21
GEP20115302B (en) 2011-10-10
JP2009502795A (ja) 2009-01-29
EP2543665A2 (fr) 2013-01-09
HRP20120573T1 (hr) 2012-08-31
SG163620A1 (en) 2010-08-30
NZ564409A (en) 2011-07-29
CR9657A (es) 2008-04-16
AU2011202047A1 (en) 2011-05-26
JP2013018789A (ja) 2013-01-31
ECSP088119A (es) 2008-02-20
MY148554A (en) 2013-04-30
ES2623608T3 (es) 2017-07-11
BRPI0613615B1 (pt) 2022-02-08
LT2284167T (lt) 2017-04-25
EP1912973A2 (fr) 2008-04-23
KR20080027853A (ko) 2008-03-28
HN2008000311A (es) 2011-01-24
HRP20170634T4 (hr) 2020-02-07
CU23916B1 (es) 2013-07-31
US8829015B2 (en) 2014-09-09
EA016856B1 (ru) 2012-08-30
NO341930B1 (no) 2018-02-19
US8343984B2 (en) 2013-01-01
GT200600315A (es) 2007-03-19
HRP20170634T1 (hr) 2017-06-30
KR20130085444A (ko) 2013-07-29
EP1912973B1 (fr) 2012-06-13
EP2284167A2 (fr) 2011-02-16
EP2284167B2 (fr) 2019-11-27
DK2284167T4 (da) 2020-03-02
PL2284167T3 (pl) 2017-07-31
EP2284168A3 (fr) 2011-04-13
JP5798101B2 (ja) 2015-10-21
EP2284168A2 (fr) 2011-02-16
HUE031791T2 (en) 2017-08-28
WO2007015870A2 (fr) 2007-02-08
ES2623608T5 (es) 2020-06-18
US20130165465A1 (en) 2013-06-27
US20130023548A1 (en) 2013-01-24
EA200800201A1 (ru) 2008-06-30
HK1116783A1 (fr) 2009-01-02
TWI406661B (zh) 2013-09-01
PH12013501590A1 (en) 2015-09-21
US8415363B2 (en) 2013-04-09
PL1912973T3 (pl) 2012-09-28
US20140343087A1 (en) 2014-11-20
PT2284167T (pt) 2017-05-15
SI1912973T1 (sl) 2012-08-31
EA201000145A1 (ru) 2010-06-30
CA2614334C (fr) 2015-04-21
AR054846A1 (es) 2007-07-18
JP5289948B2 (ja) 2013-09-11
IL214659A0 (en) 2011-09-27
DK1912973T3 (da) 2012-07-23
RS55929B2 (sr) 2020-12-31
JP2014221831A (ja) 2014-11-27
PL2284167T5 (pl) 2020-07-27
SMP200800011B (it) 2008-02-27
TW200740793A (en) 2007-11-01
DK2284167T3 (en) 2017-05-01
CU20080006A7 (es) 2011-02-24
IL188189A0 (en) 2008-03-20
EP2284167B1 (fr) 2017-02-01
EP2284167A3 (fr) 2011-03-02
EP2535337A1 (fr) 2012-12-19
ES2386974T3 (es) 2012-09-10
MX2008000899A (es) 2008-03-18
CY1119624T1 (el) 2018-04-04
CA2614334A1 (fr) 2007-02-08
KR101651288B1 (ko) 2016-08-25
PE20070214A1 (es) 2007-04-02
SI2284167T1 (sl) 2017-05-31
UA94234C2 (uk) 2011-04-26
EA013464B1 (ru) 2010-04-30
SMAP200800011A (it) 2008-02-27
ES2648288T3 (es) 2017-12-29
AU2006276204A1 (en) 2007-02-08
NO20080820L (no) 2008-04-15
KR20130077915A (ko) 2013-07-09
US20080269269A1 (en) 2008-10-30
JO3308B1 (ar) 2018-09-16
BRPI0613615A2 (pt) 2011-01-18
TNSN08029A1 (en) 2009-07-14
SI2284167T2 (sl) 2020-03-31
RS55929B1 (sr) 2017-09-29
CN102358736A (zh) 2012-02-22
WO2007015870A3 (fr) 2007-06-07
EP2543665A3 (fr) 2013-05-29
EP2535337B1 (fr) 2017-08-23

Similar Documents

Publication Publication Date Title
MA29626B1 (fr) Formes cristallines de 4-methyl-n-[3-(4-methyl -imidazol-1-yl)-5-trifluromethyl-phenyl]-3-(4- pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
MA29686B1 (fr) Sels de 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3- (4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
DK1856135T3 (da) Prodrugs af 2,4-pyrimidindiamin-forbindelser og deres anvendelser
LU92550I2 (fr) Lurasidone, facultativement sous forme de sa base libre ou de ses sels pharmaceutiquement acceptables
EA200701396A1 (ru) Триазолофталазины в качестве ингибиторов pde-2
TW200745028A (en) Novel sulphonylpyrroles
FR2882412B1 (fr) Soupape d'amortissement
NO20080265L (no) 2-(1H-indolylsulfanyl)-arylaminderivater
ITMI20052320A1 (it) Dispositivo di regolazione dell'altezza di selle o manubri
ATE390419T1 (de) 2-(piperidin-4-yl)-4,5-dihydro-2h-pyridazin-3-o - derivate als pde4-inhibitoren
CU20120123A7 (es) Formas cristalinas de la 4-metil-n-[3-(4-metil-imidazol-1-il)-5-trifluoro-metil-fenil]-3-il-pirimidin-2-il-amino)-benzamida
ITTV20050007A1 (it) Tavolo con piano d'appoggio modificabile.
FR2868857B1 (fr) Plaquette d'identification des bois auto-clippable
ITPN20050026U1 (it) "piano di cottura con piastre concave"
UY3515Q (es) Parte superior inhalador-rotahaler-m-top
ITRE20050141A1 (it) "composizione insetticida solida sublimante"
ITMC20050003U1 (it) Lente composta per la realizzazione di fondazioni antisismiche.
ITMO20050086A1 (it) 'dispositivo antifumo per sigarette o simili.'
ITAR20050016A1 (it) "smandrinatore portatile"
UA12146S (uk) Крісло м'яке